Image
Inhibition of IL-6 Signaling in the Management of Rheumatoid Arthritis Module 5

Paul Emery, MD, MA, FRCP, FMedSci; Alan J. Kivitz, MD, CPI

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications

 

This activity has been supported by an independent educational grant from Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals.

Faculty

Paul Emery, MD, MA, FRCP, FMedSci
Arthritis Research UK Professor of Rheumatology
Director, Leeds Musculoskeletal Biomedical Research Unit
Leeds Teaching Hospitals NHS Trust
Director, Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, United Kingdom

Alan J. Kivitz, MD, CPI
President, Altoona Center for Clinical Research
President, Altoona Arthritis and Osteoporosis Center
Duncansville, Pennsylvania

Course Description

This CME/CE-accredited CME Snapshot™ series of educational videos has been created for rheumatologists and other clinicians involved in treating patients with rheumatoid arthritis (RA). During each 15-minute activity, two expert rheumatologists focus on a specific aspect of long-term RA management, including practical advice on implementing international treat-to-target guidelines as well as the mechanistic profiles and clinical evidence for therapies designed to inhibit signaling via interleukin-6 (IL-6) or members of the Janus kinase (JAK) family of enzymes. Some of the modules also include 3D-animated elements to illustrate the relationships between the heterogeneous pathophysiologic mechanisms underlying RA and certain targeted biologic or synthetic disease-modifying treatment options.

Target Audience

This activity has been designed to meet the educational needs of rheumatologists and other clinicians involved in the ongoing management of patients with RA.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Discuss the clinical profiles and published evidence for current and emerging targeted inhibitors of key proinflammatory factors involved in RA pathogenesis
  • Tailor treatment regimens based on ongoing disease activity and other manifestations, therapeutic responses, and current recommendations for biologic and targeted synthetic DMARDs

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Paul Emery, MD, MA, FRCP, FMedSci: Consultant/Advisor: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.; Speakers’ Bureau: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.; Research Grant: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.

Alan J. Kivitz, MD, CPI: Consultant/Advisor: AbbVie Inc.; Vertex Pharmaceuticals Incorporated

Non-faculty

Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

CME Credit (Physicians) 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course Instructions

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who achieves a grade of 100% or better on the Post-Activity Test and who completes the Evaluation will receive a CME Certificate.
  6. All other participant who achieves a grade of 100% or better on the Post-Activity Test Questions and who completes the Evaluation will receive a Certificate of Participation.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.25

credit type CME/CE

release 09/12/2018

expiration 09/11/2019

type SnapShot